$Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma$

Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma

Lenalidomide is an effective therapeutic agent for multiple myeloma (MM). However, its efficacy in the context of chromosomal abnormalities (CA) is poorly understood. We retrospectively analyzed 83 patients with relapsed/refractory (RR) MM, who received lenalidomide plus low-dose dexamethasone (Ld),...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of hematology 2019-08, Vol.110 (2), p.228-236
Hauptverfasser:	Yoshida, Takashi, Ri, Masaki, Fujinami, Haruna, Oshima, Yoshiko, Tachita, Takuto, Marumo, Yoshiaki, Sasaki, Hirokazu, Kinoshita, Shiori, Totani, Haruhito, Narita, Tomoko, Masaki, Ayako, Ito, Asahi, Kusumoto, Shigeru, Ishida, Takashi, Komatsu, Hirokazu, Iida, Shinsuke
Format:	Artikel
Sprache:	eng
Schlagworte:	Abnormalities Adult Aged Aged, 80 and over Aneuploidy Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemical compounds Chromosome Aberrations Chromosome Banding Chromosome translocations Combined Modality Therapy Dexamethasone Dexamethasone - administration & dosage Female Health risk assessment Hematology Hematopoietic Stem Cell Transplantation Humans Immunotherapy In Situ Hybridization, Fluorescence Kaplan-Meier Estimate Lenalidomide - administration & dosage Male Medicine Medicine & Public Health Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Multiple Myeloma - therapy Oncology Original Article Patients Pharmacology Progression-Free Survival Recurrence Retrospective Studies Salvage Therapy Steroids Survival Targeted cancer therapy Therapy Translocation, Genetic Transplantation, Autologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!